Trial Information

Summary: A 12-week clinical research study to evaluate the efficacy and safety of carbamazepine extended release capsules administered once daily vs. twice daily in the treatment of manic symptoms of Bipolar I Disorder.

Study participants will receive carbamazepine extended release capsules either once daily or twice daily. Patients will be allowed to continue taking benzodiazepines, lithium, valproate, olanzapine, risperidone and/or quetiapine during the study. This study is currently enrolling.

Patients must meet the following criteria:

• Male or female outpatients over the age of 18
• Diagnosis of Bipolar I disorder, manic or mixed
• Currently experiencing a manic or mixed episode
• A history of at least one prior manic or mixed episode

Patients will be excluded for any of the following reasons:

• More than 6 mood episodes per year
• At immediate risk for suicidal or violent behavior
• Heart attack within 6 months
• History of seizure disorder
• Psychiatric disorder besides Bipolar I Disorder
• Current psychiatric hospitalization

For more information,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.